Vertex Pharmaceuticals Incorporated (VRTX) : Traders are bullish on Vertex Pharmaceuticals Incorporated (VRTX) as it has outperformed the S&P 500 by a wide margin of 12.35% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.15%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 5.6% in the last 1 week, and is up 15.14% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $100.46 and $99.77 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $102.94. The buying momentum continued till the end and the stock did not give up its gains. It closed at $102.43, notching a gain of 2.14% for the day. The total traded volume was 1,113,873 . The stock had closed at $100.28 on the previous day.
The stock has recorded a 20-day Moving Average of 9.67% and the 50-Day Moving Average is 12.59%. Vertex Pharmaceuticals Incorporated is up 19.75% in the last 3-month period. Year-to-Date the stock performance stands at -18.6%.
Vertex Pharmaceuticals Incorporated (VRTX) : The highest level Vertex Pharmaceuticals Incorporated (VRTX) is projected to reach is $155 for the short term and the lowest estimate is at $75. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $116.42 and the possibility the share price can swing is $20.33.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.